Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trialLaurent Peyrin‐Biroulet, Peter Bossuyt, Elham Ostad-Saffari et al.|The Lancet. Gastroenterology & hepatology|2021Cited by 96
Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease—A Multicenter Retrospective European StudyUri Kopylov, Marc Ferrante, Bram Verstockt et al.|Inflammatory Bowel Diseases|2018Cited by 70
Environmental Factors Associated With Risk of Crohn’s Disease Development in the Crohn’s and Colitis Canada - Genetic, Environmental, Microbial ProjectMingyue Xue, Scott B. Snapper, Haim Leibovitzh et al.|Clinical Gastroenterology and Hepatology|2024Cited by 33
DOP001 Effectiveness and safety of vedolizumab in anti-TNF naïve patients with inflammatory bowel disease: a multicentre retrospective European Crohn’s and Colitis Organisation studyUri Kopylov, Marc Ferrante, Bram Verstockt et al.|Journal of Crohn s and Colitis|2018Cited by 4